Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. - Wikidata - wikimedia - TriplyDB

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

http://www.wikidata.org/entity/Q37714189

about

Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction.Antithrombotic Activity of DAB-15, a Novel Diazepinobenzimidazole Compound.

P2860

Q37288480-3344B8BE-32EE-4190-BD72-ADB9B36C3B98 Q53945045-EB3867A7-1E10-4F54-99F3-6E75C37D6A19

P2860

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

http://www.wikidata.org/entity/Q37714189

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

@en

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

@nl

type

label

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

@en

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

@nl

prefLabel

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

@en

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

@nl

P1433

Q37714189-EF83E830-768E-41AE-86C4-549AE8721630

P1476

Q37714189-38855C7F-0D7E-4F62-8415-281EB13A6E85

P2093

Q37714189-924D1AB8-8315-4C9D-A616-865341367B01

Q37714189-F44EC9A9-9866-4AFD-8160-DA1ADBF2BABE

P2860

Q37714189-03CBA83B-4D84-44C9-ABAA-524E1E504396

Q37714189-0783406E-7BE0-43BD-B6CD-4F075938655A

Q37714189-0A609BC1-7C9E-4B51-B7F7-37BD7AD5BBF6

Q37714189-0D9E5C39-6462-4A88-A574-9156E9B30E76

Q37714189-20744D08-9377-421B-9567-D4A6FF59A967

Q37714189-20C81362-90D4-41B3-8585-70D61D98536F

Q37714189-2577DA18-C097-434F-9185-4D3A9E13278B

Q37714189-271C39EF-FB1B-4F8C-9560-A5E597287F5C

Q37714189-2D850EBC-151D-4F42-988E-A42AECAEB027

Q37714189-2F085B70-3B66-4136-861E-BFAB59A9FC6A

P304

Q37714189-2F33D909-9E67-4218-9C42-9AEDFDC11995

P31

Q37714189-9228AD7C-4677-47BE-BE45-F7F18F9ECB7E

P356

Q37714189-3870BE44-D1AA-431B-8986-6F6EE613088A

P433

Q37714189-B2CA57F3-877E-47D8-AB1A-9B816934D688

P478

Q37714189-C9A36733-AA55-4DF6-8425-49E818A67092

P50

Q37714189-82AD03E9-AE07-4EA9-87E9-322CA0860555

P577

Q37714189-143ECE5C-9767-41C3-A3AA-E99CA601F9B3

P698

Q37714189-0755DC60-A734-4759-869B-80745ACA90BF

P356

1076029609355589

P1433

Clinical and Applied Thrombosis-Hemostasis

P1476

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist

@en

P2093

Jawed Fareed

http://www.w3.org/2001/XMLSchema#string

Walter P Jeske

http://www.w3.org/2001/XMLSchema#string

P2860

Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond

Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy

Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies

Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

P304

170-176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1076029609355589

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20299391

http://www.w3.org/2001/XMLSchema#string